ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
Adam Grossman, the President and Chief Executive Officer of ADMA
Biologics, Inc. (the Company), is scheduled to give a corporate
presentation to potential investors of the Company at the
Jefferies 2017 Healthcare Conference on June 8, 2017 at 8:30 a.m.
EST (the Investor Presentation). A copy of the slides comprising
the Investor Presentation is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
In accordance with General Instruction B.2 on Form 8-K, the
information set forth in this Item 7.01 and the Investor
Presentation slides, attached to this report as Exhibit 99.1, are
furnished and shall not be deemed to be filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall such information be deemed incorporated
by reference in any filing under the Exchange Act or the
Securities Act of 1933, as amended.
Please refer to Exhibit 99.1 for a discussion of certain
forward-looking statements included therein and the risk and
uncertainties related thereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| ExhibitNo. | Description | |
| 99.1 | ADMA Biologics, Inc. June 2017 Investor Presentation. |
About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
